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Abstract
Rationale Acute tryptophan depletion (ATD) is a widely
used method to study the role of serotonin (5-HT) in affect
and cognition. ATD results in a strong but transient
decrease in plasma tryptophan and central 5-HT synthesis
and availability. Although its use is widespread, the
evidence that the numerous functional effects of ATD are
caused by actual changes in 5-HT neuronal release is not
very strong. Thus far, decreases in 5-HT efflux (thought to
reflect synaptic release) were only reported after chronic
tryptophan depletion or when ATD was combined with
blockade of 5-HT reuptake.
Objective With the current experiment, we aimed to study
the validity of the method of ATD by measuring the extent
to which it reduces the efflux of 5-HT (and dopamine) in
the prefrontal cortex in the absence of reuptake blockage.
Materials and methods We simultaneously measured in
freely moving animals plasma tryptophan via a catheter in
the jugular vein and 5-HT and DA efflux in the medial
prefrontal cortex through microdialysis after ATD treatment.
Results ATD reduced plasma tryptophan to less than 30%
of control, without affecting 5-HT or DA efflux in the
prefrontal cortex, indicating that even strong reductions of
plasma tryptophan do not necessarily result in decreases in
central 5-HT efflux.
Conclusion The present experiment showed that reductions
in plasma tryptophan, similar to values associated with
behavioural effects, do not necessarily reduce 5-HT efflux
and suggest that the cognitive and behavioural effects of ATD
may not be (exclusively) due to alterations in 5-HT release.
Keywords Medialprefrontalcortex.Tryptophan.
Microdialysis.Serotonin (5-HT).Dopamine(DA)
Introduction
Awidely applied method for the study of the role of serotonin
(5-HT) in cognition and affective processing is acute
tryptophan depletion (ATD; Biggio et al. 1974; Fadda et al.
2000b; Fadda 2000). Through dietary depletion of the
essential amino acid tryptophan, peripheral and central
availability of this precursor of serotonin can be rapidly
lowered (Biggio et al. 1974;M o j ae ta l .1989). This, in turn,
leads to reduced synthesis of the monoamine 5-HT (Gessa
et al. 1974) and reduced central availability of this neuro-
transmitter (Fadda et al. 2000b;L i e b e ne ta l .2004a).
Since the introduction of this method, ATD has been
successfully applied in both human and rodent research and
has implicated the serotonergic system in cognition (e.g.
memory impairments, reduced attention and increased
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(T). J. Meerkerk I M. G. P. Feenstraimpulsivity) and affective processes (e.g. relapse of de-
pressed patients, mild depressive state, aggression and
irritability; Fadda 2000; Riedel et al. 2002). Various studies
have, furthermore, reported ATD-induced effects on typical
‘prefrontal’ tasks, like reversal learning (Rogers et al. 1999;
Finger et al. 2007) and intra- and extradimensional set
shifting (Park et al. 1994), but also ATD-induced changes
in prefrontal cortex (PFC) activity as measured with
functional magnetic resonance imaging (Rubia et al. 2005;
Allen et al. 2006; Evers et al. 2005).
Recent literature, however, shows that the reported
cognitive and behavioural effects of ATD are not always
reproducible and suggests that ATD as a method for
studying 5-HT depletion is particularly suitable for sub-
populations that show a vulnerability to 5-HT dysregulation
(Fadda 2000; Booij et al. 2003; Fusar-Poli et al. 2006; Jans
et al. 2007). These subgroups include remitted depressed
patients (Bremner et al. 1997; Young and Leyton 2002;
Neumeister et al. 2004), females (Nishizawa et al. 1997;
Schmitt et al. 2000; Booij et al. 2002; Ellenbogen et al.
1996) and subjects with certain genetic variations in the 5-
HT transporter gene (Roiser et al. 2006; Finger et al. 2007).
Fusar-Poli et al. (2006) furthermore suggest that the effects
observed after ATD might not be mediated solely through a
5-HT-related mechanism, but rather indirectly via compen-
satory mechanisms of other transmitter systems (see also
Praschak-Rieder et al. 2004). One candidate for this is
dopamine (DA). Although direct evidence for ATD-induced
effects on other transmitter systems, including DA, is
lacking, there is compelling evidence that 5-HT can directly
regulate dopaminergic activity and, consequently, function
(for a current review, see Alex and Pehek 2007).
On the other hand, evidence for the effect of ATD on the
actual neuronal release of 5-HT in the brain is sparse and,
in most cases, indirect. Human studies are limited in their
measurement to imaging studies of central 5-HT synthesis
(Nishizawa et al. 1997), 5-HT receptor occupation (Udo de
Haes et al. 2002; Praschak-Rieder et al. 2004) and cere-
brovascular fluid measurement of tryptophan and 5-HT
metabolism (Carpenter et al. 1998). Although these studies
partially confirm reduced synthesis of 5-HT and do report
lowered levels of the metabolite of 5-HT in cerebrospinal
fluid, evidence for reduced release of 5-HT is absent.
A number of rodent studies, in general employing the
same method of ATD, suggest that in addition to reduced
tryptophan availability and reduced 5-HT synthesis, the
actual synaptic release of 5-HT is lowered. Evidence for the
assumption that ATD does in fact lower 5-HT release is,
however, inconclusive. Microdialysis studies have been
able to show reduced extracellular 5-HT after ATD only in
the presence of a selective serotonin reuptake inhibitor
(SSRI; Fadda et al. 2000b; Bel and Artigas 1996;
Stancampiano et al. 1997), while there are no reports that
show decreased or unaffected 5-HT efflux in animals that
are not treated with SSRIs. This is an important observa-
tion, as non-physiological blockade of serotonin reuptake
can interfere with normal transmitter release, making a
clear-cut interpretation of the data difficult. Furthermore,
Marco and Meek (1979) show that SSRI treatment in rats
can reduce synthesis, which, in turn, could augment the
depletion of 5-HT pools induced by ATD (see also Carlsson
and Lindqvist 1978; Moret and Briley 1997; Fuxe et al.
1982 and Yamane et al. 2001).
In line with the evidence for prefrontal mediated effects
of ATD mentioned earlier, we examined the effect of ATD
on extracellular concentrations of both 5-HT and DA in the
PFC in spontaneously active, and behaviourally stimulated,
animals. We aimed to investigate whether successful
lowering of blood plasma tryptophan concentration with
ATD leads to a reduction of medial prefrontal 5-HT efflux
in the absence of a serotonergic reuptake blockade.
Materials and methods
All experiments were approved by the Animal Experimen-
tation Committee of the Royal Netherlands Academy of
Arts and Sciences and were carried out in agreement with
Dutch Laws (Wet op de Dierproeven, 1996) and European
regulations (Guideline 86/609/EEC).
Subjects
Subjects were 20 male outbred Wistar rats (Harlan/CPB,
Horst, The Netherlands) weighing 175–200 g at arrival.
Upon arrival, the animals were socially housed in groups of
four in standard type IV macrolon cages where they were
kept under a reversed day/night cycle (dimmed red light
from 7 A.M. until 7 P.M., white light from 7 P.M. until 7 A.M.)
for the duration of the experiment. After surgery and during
experimental procedures, the animals were kept in individ-
ual cages (25×25×35 cm).
Surgery
Two weeks after arrival, the animals were subjected to
surgery for placement of a jugular vein catheter and
implantation of bilateral microdialysis probes. The weight
of the animals at time of the surgery was 297–332 g. Rats
were anesthetised with intramuscular Hypnorm (0.24 mg/kg
fentanyl citrate and 7.5 mg/kg fluanisone, Janssen);
subcutaneous Dormicum (0.75 mg/kg midazolam, Roche)
was given for muscle relaxation. A silicon catheter was
placed in the right jugular vein to allow for blood sampling,
as described by Steffens (1969). For the subsequent
implantation of the microdialysis probes, the animals were
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−2.5 mm. Bilateral probes were then placed in the medial
PFC at an angle of 12° (A+30 L±18; V−55). Both
microdialysis probes and jugular vein cannula were secured to
the scull with dental cement and two cranial screws. Postoper-
ative pain reduction was achieved with Temgesic (0.10 mg/kg
buprenorphine, Schering-Plough), 0.03 ml/100 g b.w. s.c
approximately 2 h after surgery. After surgery, the animals
returned to individual cages for the remainder of the
experiments.
Experimental procedure
Approximately 1 week after surgery, the animals were
assigned to either the experimental or control condition,
with the body weight of the animals matched between
groups. Fourteen hours before the experiment, food was
removed from the home cages. On the day of the
measurement, the animals were transferred to the experi-
mentation room where they were kept in cages that
contained their own bedding material. For the duration of
the experiment, the animals were connected to the micro-
dialysis tubing and blood sampling lines, which were
attached to a swivel and counterbalanced beam out of
reach of the animals. In this way, the animals were
unrestricted in their movement, and the collection of blood
samples could be achieved without handling the animals.
The collection of hourly blood samples started as soon as
stable efflux of DA and 5-HT was observed (see below),
which was approximately 2 h after connection. A first
administration of the diet (see below) followed the initial
blood sampling; a second administration was given 90 min
after the first. Two and a half hours after the first diet
administration, the rats were subjected to 20 min of
‘novelty’ stimulation.
During this period, the animals were given access to an
identically shaped cage, filled with new bedding material,
by means of an opaque sliding door connecting the
measurement cage with the ‘novelty’ cage.
Optical movement detectors, connected to a PC running
locally written software, were placed on top of the cages to
detect possible changes in locomotor behaviour due to diet
administration.
All animals were tested individually on separate days. A
radio played to mask background noise and minimise
interference from experimental procedures.
Treatment
The experimental rats (TRP minus group) were treated
orally with a protein–carbohydrate mixture lacking trypto-
phan (TRP; 4.0 g/kg Solugel P™ and 2.0 g/kg Maltodex-
trine) in a volume of 10 ml/kg (see Table 1). Two diet
administrations were given, spaced 90 min apart. Control
animals received the same mixture with added TRP (0.28%
TRP of total protein). The exact composition of the mixture
and the procedure for administration is identical to that
described in Lieben et al. (2004a). To minimise stress, the
rats were daily handled and habituated to oral injections
with normal tap water (10 ml/kg). To minimise TRP intake
through the normal rat chow, food was removed from the
home cages 14 h before the start of the experiment. Water,
however, remained freely available during this period.
Blood sampling and quantification of TRP content
On the experimental day, hourly blood samples were taken
via the jugular vein catheter and analysed for TRP content.
We collected six consecutive blood samples during the
experiment. The first sample was taken after a stable
microdialysis baseline was established and just before the
first diet administration was given. Before the start of the
experiment, the rats were habituated to blood sampling to
minimise stress (i.e. a syringe was attached to the catheter
and blood was withdrawn and immediately returned).
Table 1 Composition of the nutritional mixture and determination of
the amino acids content of the gelatin-based protein
Mixture Values
Protein (Solugel P®) in 100 ml tap water 100
Aspartic acid + asparagine 5.2
Glutamic acid + glutamine 9.3
Hydroxyproline 12.1
Serine 3.1
Glycine 22.5
Histidine 0.5
Arginine 8.8
Threonine 1.1
Alanine 9.3
Proline 13.3
Tyrosine 0.4
Valine 2.1
Methionine 0.6
Cysteine 0.2
Isoleucine 1.4
Leucine 3.0
Hydroxylysine 1.4
Phenylalanine 1.9
Tryptophan 0.1
Lysine 3.6
Carbohydrate (Malthodextrine) in 80 ml tap water 50
KCl 0.094
CaCl2·2H2O 2.32
L-Tryptophan (Tryp minus group) 0
L-Tryptophan (control group) 0.28
The composition of the administered mixture used in the current
experiment is depicted in bold. The amino acid content (%) of the
protein was obtained from PB Gelatins, Tessenderlo, Belgium.
Psychopharmacology (2007) 195:377–385 379Blood samples (200 μl) were collected in heparin-filled
tubes and deproteinised with 5-sulfosalicylic acid (5%).
After centrifuging (15 min at 3,220×g), the samples were
stored at −80°C until analysis.
After completion of the experiment, the plasma samples
were thawed at 4°C, and 20 μl supernatants were
transferred to a high-performance liquid chromatograph
(HPLC) for analysis (Waters 600E pump and Waters
717plus autosampler, Waters Chromatography b.v., Nether-
lands; Jasco FP-920 intelligent fluorescence detector, Jasco,
Benelux B.V., Netherlands and Shimadzu Class-vp™
software v.5.03 Shimadzu Duisburg, Germany).
The mobile phase consisted of 0.06 mol/l sodium acetate,
9mmol/lcitric acid,0.37mmol/lsodium1-heptanesulfonate
(HSA) and 12.5% methanol in milliQ water. The flow rate
was kept constant at 1.0 ml/min. Separation of TRP from
other components was achieved with a Supelcosil column
(LC-18-DB 25 cm×4.6 mm×5 μm), with a 2-cm guard-
column of the same material (Supelco Superguard™,
Supelco USA), at a constant temperature of 40°C. Quanti-
fication was achieved by means of fluorescence detection,
withtheexcitation wavelengthsetat335nmand anemission
wavelength of 440 nm. TRP content was measured against a
calibration curve of an external TRP standard.
Microdialysis probes and measurements
Concentric dialysis probes, manufactured and routinely
used in this laboratory (Feenstra and Botterblom 1996),
were constructed from fused silica (i.d. 0.075 mm) pro-
tected by 25-G needles as inlet and outlet. A Hospal
membrane (o.d. 0.32 mm, i.d. 0.24 mm) with 3-mm
exposed length was fitted for these experiments.
A week after surgery (Feenstra et al. 2000), the animals
were transferred to the test room where the dialysis probes
were connected to PEEK (polyetheretherketone)-tubing
(o.d. 0.51 mm; i.d. 0.13 mm; Aurora Borealis, Netherlands)
attached to a dual-channel swivel (Pronexus, Skärholmen,
Sweden). A Univentor 801 microinfusion syringe pump
deliveredaringersolution(145mmol/lNaCl,1.2mmol/lCaCl2,
2.7 mmol/l KCl, 1.0 mmol/l MgCl2) at a flow rate of
1.3 μl/min. Dialysate was directly introduced into the
electrically actuated HPLC injector (Valco, VICI, C6W),
and 50 μl was injected every 15 min. DA and 5-HT were
separated on a Supelcosil column (LC-18-DB 25 cm×
4.6 mm×5 μm) and detected by means of an ANTEC VT-
03 electrochemical flowcell (50-μm spacer) set at +0.65 V
against a Ag/AgCl reference electrode.
The mobile phase consisted of 0.06 mol/l sodium
acetate, 9 mmol/l citric acid, 0.37 mmol/l HSA and
12.5% methanol in milliQ water. The flow rate was kept
constant at 1.0 ml/min; a pulse damper (ANTEC, Leyden)
was placed with the column inside the DECADE detector
unit (ANTEC) and kept at a constant temperature of
40°C.
The DECADE unit was programmed to automatically
make an injection every 15 min and simultaneously start
registration of the detector output. 5-HT and DA content
was measured against a calibration curve of an external
standard using Shimadzu Class-VP™ software (Shimadzu,
v.5.03). The detection limit (ratio signal to noise=2) was
0.15 pg of 5-HT and DA injected onto the column.
Drugs and chemicals
The Gelatine hydrolysate (Solugel P™) was obtained from
PB Gelatins (Tessenderlo, Belgium). Glucodry 200 was
obtained from the Amylumgroup (Koog aan de Zaan, the
Netherlands). Potassium chloride (KCl), calciumchloride–
dihydrate (CaCl2·2H2O), sodium chloride (NaCl), sodium
1-heptane sulfonate (HSA), methanol and tryptophan were
obtained from Sigma-Aldrich Chemie, Germany. 5-Sulfosa-
licyclic acid dehydrate and magnesium chloride hexahydrate
(MgCl2·6H2O) were obtained from Merck Schuchhardt.
Sodium acetate and citric acid were purchased at Janssen
Chimica, Geel, Belgium
Histological examination
After completion of the experiments, the rats were
humanely killed by inhalation of a mixture of CO2/O2
(70/30) followed by 100% CO2. The brains were rapidly
taken out of the skull and frozen at −20°C. Coronal
(20 μm) sections were cut on a cryostat and stained with
thionine for examination with the microscope for the
precise location of the microdialysis probes.
Data analysis
Changes in extracellular concentration of DA and 5-HT
were calculated as deviations from the baseline defined as
the last two samples preceding the first diet administration.
Changes in plasma levels of TRP were compared to the first
sample preceding diet administration. ‘Movement-counts’,
in arbitrary units, registered by the optical movement
detector were taken as measure for possible changes in
activity. All data were analysed using a repeated measures
analysis of variance (ANOVA) with time as within-factor
and group/treatment as between-factor. If indicated by the
Mauchly’s test of sphericity, the number of degrees of
freedom was adjusted by a Huynh–Feldt correction.
If indicated by an ANOVA group or interaction effect,
subsequent evaluation of the effects of the treatment on
individual samples was done by the Student Newman–
Keuls test with repeated measures in which all samples are
mutually compared. The level of significance was p<0.05.
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and general activity during the measurement was assessed
by recalculation of a baseline from the two samples before
novelty exposure. The data were then analysed as described
above. All data are presented as means±SEM.
Results
Histological examination and animal exclusion Histological
sections were examined for placement of the microdialysis
probes. Data from rats with incorrectly placed probes were not
includedintheanalysis.After exclusion,boththe control group
and the TRP minus group included eight animals.
Plasma concentrations Figure 1 showsthechangeofplasma
tryptophan concentrations for both the control and treated
group. Due to blockade of several jugular vein cannulas, the
control group included seven and the TRP minus group, five
animals. Average plasma concentrations (μg/ml) of trypto-
phanfor the initialbaselinesampleswere18.80±11.92for the
control group and 21.51±15.64 for the TRP minus group.
A repeated measures ANOVA with group (TRP minus/
control) as between-subjects factor and time as within-
subjects factor resulted in a main effect of time [F(4.45,44.50)=
3.07 p<0.03] and group [F(1,10)=38.76, p<0.0005] as well
as a group/time interaction [F(4.45,10)=8.09, p<0.0005]. An
additional t test revealed a significant reduction of the TRP
minus group compared to the control group (time point 3: t=
6.00, p<0.0005; time point 4: t=7.66, p<0.0005; time point
5: t=5.76, p<0.0005; time point 6: t=3.15, p=0.01; Fig. 1).
In contrast to the control group that showed an initial increase
in plasma tryptophan (up to 167%) and returned to baseline
values [F(5,30)=3.50, p<0.02], the TRP minus group showed
a persistent decrease in plasma tryptophan after the second
administration, with a minimum of 29% of baseline 2 h after
the first diet administration [F(2.51,10.06)=15.26, p=0.001]. A
simple contrast ANOVA for the control group revealed that
time points 3 and 4 were significantly different from
baseline; for the TRP minus, time points 3, 4, 5 and 6 were
different from baseline.
Microdialysis
Microdialysis of 5-HT Figure 2a shows the relative change,
compared to two baseline samples, in 5-HT efflux over the
entire day. An ANOVA with repeated measures revealed no
significant group [F(1,14)=0.57, p>0.4], time [F(13.49,188.78)=
1.19, p>0.2] or interaction effect [F(13.49,14)=0.97, p>0.4].
Average transmitter concentrations (pg/50 μl) of serotonin
for the initial baseline samples were 1.41±0.27 (mean±
SEM) for the control group and 1.48±0.23 (mean±SEM) for
the TRP minus group.
No significant differences between treated and control
group were observed during novelty exposure when values
were expressed relative to the original baseline or to a
recalculated baseline just before the exposure.
Microdialysis of DA Figure 2b shows the relative change,
compared to two baseline samples, in DA efflux over the
entire day. An ANOVA with repeated measures revealed a
significant effect of time [F(6.95,60.58)=2.76, p<0.02], but
not of group [F(1,14)=1.62, p> 0 . 2 ]o ro fi n t e r a c t i o n
[F(8.14,14)=0.98, p>0.4]. Subsequent analysis of individual
groups showed no time effect for either group.
Average extracellular transmitter concentrations (pg/50 μl)
of dopamine for the initial baseline samples were 0.64±
0.15 (mean±SEM) for the control group and 0.72±0.16
(mean±SEM) for the TRP minus group.
No significant differences between treated and control
group were observed during novelty exposure when values
were expressed relative to the original baseline or to a
recalculated baseline just before the exposure.
Movement detection
Figure 2c shows the average number of activity counts for
both the control group and the TRP minus group. Average
movement counts for the initial baseline samples were
123.59±17.71 (mean±SEM) for the control group and
110.38±14.22 (mean±SEM) for the TRP minus group.
These data support the behavioural observation of sustained
Fig. 1 Plasma tryptophan concentration. Relative concentration
(mean±SEM) of tryptophan in plasma compared to baseline. Open
triangles correspond to the TRP minus group; closed squares
correspond to the control group. The vertical grey bars correspond
to, respectively, first diet administration, second diet administration
and novelty exposure. Asterisk indicates a significant difference
between the two groups, p<0.05; sigma indicates a significant
difference compared to the baseline value, p<0.05
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ing and explorative movement).
A repeated measures ANOVA revealed a significant
effect of time over the entire day [F(10.27,143.72)=2.69, p<
0.005]. No group [F(1,14)=0.42, p>0.5] or interaction
[F(10.27,14)=0.55, p>0.8] effect was observed.
The novelty stimulation did not cause any differential
effect on overall activity.
Discussion
To gain insight into the relation between ATD and the
release of serotonin (5-HT) in the prefrontal cortex, we
measured plasma levels of tryptophan and, simultaneously,
PFC efflux of 5-HT and DA in animals that underwent
ATD. In line with current literature (Lieben et al. 2004a),
ATD induced a rapid decline of free plasma tryptophan
w i t h i n2ho ft h ei n i t i a la d m i n i s t r a t i o nt h a tl a s t e d
throughout the experimental procedure. However, despite
this reduction, efflux of prefrontal serotonin (5-HT), as
measured in the medial PFC with microdialysis, was
unaffected in these animals. In contrast to previous studies,
these measurements, in behaviourally active animals, were
performed in the absence of a serotonergic reuptake
blocker. These results indicate that successful lowering of
plasma tryptophan, to levels associated with behavioural
effects, does not necessarily induce lowering of 5-HT
efflux. Considering the widespread use of ATD as a method
for studying the role of serotonin in behavioural and
cognitive research, these findings are especially relevant.
The current experiment combined blood sampling
through a chronic jugular vein catheter with online micro-
dialysis measurements of 5-HT and DA. This combination
of techniques was used to ensure that blood sampling did
not hinder the animals in their behaviour or cause unwanted
effects on transmitter release.
In line with current literature, we measured a rapid
decrease of plasma tryptophan of more than 70%. Although
the possibility exists that a greater reduction of plasma
tryptophan, which can be achieved with chronic tryptophan
depletion (Fadda et al. 2000a), could have induced a
reduction of 5-HT efflux, it would not explain the effects
on behaviour and affect observed after tryptophan deple-
tions of a magnitude similar to those observed in the current
experiment (e.g. Riedel 2004; Lieben et al. 2004b; Delgado
2006). The 4.5-h time-window in which we measured is
well within the period for which behavioural effects have
been reported, reducing the likelihood that a decrease in 5-
HT efflux would have been observed had we measured for
a longer period. Lack of sensitivity of the measurement
equipment does not seem likely either; with the current
detection limit, reductions of either transmitter would have
been measurable.
The absence of a clear effect of novelty stimulation on
eithergeneral activity or transmittereffluxmightsuggestthat
the animals were inactive. However, behavioural observa-
tion, as well as quantitative movement detection, indicates
otherwise, showing that the animals were in fact active
throughout the measurements (e.g. grooming, and explor-
ative behaviour), although the active novelty exposure did
not induce the expected increase in locomotor activity.
Literature data from both human and rodent studies
show that ATD leads to lowering of plasma tryptophan
(Biggio et al. 1974; Moja et al. 1989) and decreased
synthesis (Gessa et al. 1974) and availability of central 5-
HT (Ashley and Curzon 1981; Fadda et al. 2000b; Lieben
et al. 2004a), but, to date, it has not been convincingly
shown that the ATD lowers efflux of 5-HT in the brain. The
Fig. 2 Microdialysis of 5-HT and DA and general activity counts.
Relative change in extracellular 5-HT and DA (mean±SEM) and
movement compared to baseline. Open triangles correspond to the
TRP minus group; closed squares correspond to the control group. a 5-
HT, b DA and c movement counts. The vertical grey bars correspond
to, respectively, first diet administration, second diet administration and
novelty exposure. No significant changes were observed
382 Psychopharmacology (2007) 195:377–385few rodent studies that do show reduced efflux after ATD
either used chronic treatment with a tryptophan-deficient
diet (Fadda et al. 2000b; Van der Stelt et al. 2004)o r
combined the measurements with drugs that prevent
reuptake of 5-HT (Fadda et al. 2000b; Bel and Artigas
1996; Stancampiano et al. 1997; but see Bel and Artigas
(1996) who observe an increase, rather than a decrease, of
5-HT efflux in the PFC after ATD in rats on free food). To
the best of our knowledge, the current experiment is the
first to report on the effect of ATD on prefrontal 5-HT
efflux after overnight fasting in the absence of a reuptake
blocker, an experimental design that parallels the behav-
ioural studies in both rodents and human subjects. As
pointed out in the “Introduction”, this is especially
important, as the addition of reuptake inhibition can lead
to decreased 5-HT synthesis, and thus, augment the effect
of ATD. In light of the behavioural effects observed after
acute tryptophan depletion and the general notion that a
reduction of synaptic 5-HT release underlies these effects,
understanding the effect of ATD on 5-HT efflux, which is
thought to reflect release, is essential.
Our data seem to suggest that successful tryptophan
depletion does not alter 5-HT release. ATD, however, has
convincingly shown to be an effective method to manipu-
late mood and induce cognitive/behavioural effects in both
humans (Fusar-Poli et al. 2006; Riedel et al. 2002) and
rodents (Fadda 2000; Riedel 2004). This apparent discrep-
ancy will be discussed in the next section.
Although mood effects after ATD have been reported
across populations of subjects, groups with vulnerability for
5-HT dysregulation (e.g. remitted depressed patients,
women and people that show a genetic variation in the 5-
HT transporter gene) seem particularly sensitive to ATD
(Delgado 2006; Booij et al. 2002; Moore et al. 2000;
Neumeister 2003; Riedel et al. 2002; Roiser et al. 2006;
Jans et al., 2007). It is argued that especially these groups
are sensitive to ATD because they already show a reduced
availability of central 5-HT that is further reduced by
tryptophan depletion. In contrast to non-vulnerable sub-
jects, these subpopulations will be less able to compensate
for a temporary reduction in 5-HT synthesis and will ex-
perience a greater impact of ATD. Likewise, SSRI-treated
animals will experience depletion of 5-HTstores (Marco and
Meek 1979) and more readily show decreased 5-HT efflux
after ATD than unmedicated rats. Measurements of indices
of 5-HT release in response to ATD in ‘vulnerable’ rodents,
like serotonin transporter knockout animals (Holmes et al.
2003), or females have not been performed.
In contrast to effects on mood, behavioural and cognitive
effects are generally observed in a broader population that
also includes healthy subjects (for a review, see Riedel et al.
2002) that do not show a particular sensitivity to 5-HT
dysregulation.
The most parsimonious explanation that can unify those
observations with the current data is that brain areas outside
the medial PFC, which have not been measured in the
present experiment, might mediate the behavioural effects.
As the innervation of 5-HT in the brain is not uniform
(McQuade and Sharp 1997; see for an overview Frazer and
Hensler 1999) and some areas appear to be more sensitive
to ATD than others (Lieben et al. 2004a; Fusar-Poli et al.
2006), the absence of 5-HT efflux reductions in the medial
PFC might not reflect ATD-induced changes in other
(prefrontal) areas.
However, this explanation seems to hold only partially at
best. As mentioned in the “Introduction”, ATD studies have
implicated prefrontal 5-HT in various ‘prefrontal’ tasks, like
reversal learning (Rogers et al. 1999; Finger et al. 2007)
and intra-, extradimensional set shifting (Park et al. 1994),
and shown ATD-induced changes in PFC activity (Rubia
et al. 2005; Allen et al. 2006; Evers et al. 2005).
The possibility that other transmitter systems might
mediate ATD effects (Fusar-Poli et al. 2006) was investi-
gated by simultaneous measurements of DA. As we
reported that DA efflux did not respond to the ATD, the
current data cannot confirm this hypothesis, although other
possible transmitters remain to be investigated.
While it is not possible to extrapolate these findings to
brain areas outside the medial PFC, our present data show
that an effective reduction of plasma tryptophan with ATD
does not necessarily imply a similar reduction in 5-HT
efflux. As ATD continues to be an important and widely
used paradigm to study specific roles of 5-HT, it is
important to clarify through which mechanism ATD exerts
its effects and to what extent changes in 5-HT contribute to
the functional effects of ATD.
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